|
|
|
| Meta-analysis of the immune effects of inactivated H7N9 influenza vaccine |
| WU Xiao-xue*, GOU Xiao-qin, SHI Yu, ZHANG Ke, QIAN Yuan, SU Min, HUANG Jun-qiong
|
| *Clinical Lab of The Affiliated Hospital of Zunyi Medical College,Zunyi,Guizhou 563000,China |
|
|
|
|
Abstract Objective To evaluate the immune effects of inactivated H7N9 influenza vaccine.Methods We searched several common databases（The Cochrane Library,PubMed,China Biology Medicine disc,China National Knowledge Infrastructure,etc.）for research articles about immune effects of H7N9 influenza vaccine published from the time the database built to July 10th of 2018,using H7N9 and vaccine as keywords. After screening the articles according to the inclusion and exclusion criteria,we assessed the quality of the studies and then employed seroconversion rate（SCR）as an outcome indicator to analyze the immune effects of different doses and adjuvants.Results We recruited 5 articles on inactivated H7N9 influenza vaccine from 1 679 articles. The sample size was 2 579. The results of the meta-analysis showed that the rate difference（RD）values of SCR in each dose group after the first dose ranged from 1% to 10%,which indicated a poor protective effect;after the second dose of immunization,the RD values of SCR in the vaccines without adjuvants ranged from 13% to 19%,which was not effective enough;the RD values of SCR in the vaccines with adjuvants ranged from 62% to 69%,which met the licensing criteria for influenza vaccine;better results could be achieved when immunized with two doses of vaccines with adjuvants（ RR=1.19,95%CI：1.02-1.39）;vaccines with AS03 or MF59 at the lowest dose of 3.75 μg had the same immune effects as ones at a dose of 15 μg;vaccines with AS03（RD=89%,95%CI：85%-93%）were superior to those with MF59（RD=42%,95%CI：9%- 75%）.Conclusion Inactivated H7N9 influenza vaccines could achieve good immune effects when inoculated two doses with adjuvants,and the minimum effective dose was 3.75 μg.
|
|
Received: 10 October 2018
Revised: 02 December 2018
Published: 04 March 2019
|
|
|
| Fund:国家自然科学基金（81860376） |
|
|
|
[1] ZHOU L,REN R,YANG L,et al.Sudden increase in human infection with avian influenza A(H7N9)virus in China,September-December 2016[J] . Western Pac Surveill Response J,2017,8(1):6-14.
[2] KILE J C,REN R,LIU L,et al.Update:Increase in human infections with novel Asian lineage avian influenza A(H7N9)viruses during the fifth epidemic-China,October 1,2016-August 7,2017[J] . MMWR,2017,66(35):928-932.
[3] WATANABE T,KISO M,FUKUYAMA S,et al.Haracterization of H7N9 influenza A viruses isolated from humans[J]. Nature,2013, 501(7468):551-555.
[4] LI Q,ZHOU L,ZHOU M,et al.Epidemiology of human infections with avian influenza A(H7N9)virus in China[J]. New Engl J Med,2014,370(6):520-532.
[5] 郭万申,徐瑾,吴俊,等. 季节性流感裂解疫苗安尔来福(R)的安全性、免疫原性及与H7N9禽流感病毒的交叉免疫研究[J]. 中华流行病学杂志,2014,35(8):949-952.
[6] SHEN Y,HU Y,MENG F,et al.Safety,immunogenicity and cross-reactivity of a Northern hemisphere 2013-2014 seasonal trivalent inactivated split influenza virus vaccine,Anflu(R)[J]. Human Vaccine & Immunotherapeutics,2016,12(5):1229-1234.
[7] 胡昱,李倩,汪颖,等. 65岁及以上老年人接种TIV一年内免疫持久性的Meta分析[J]. 预防医学,2017,29(11):1109-1114,1118.
[8] MULLIGAN M J,BEMSTEIN D I,WINOKUR P,et al.Serological responses to an avian influenza A/H7N9 vaccine mixed at the point-of-use with MF59 adjuvant:a randomized clinical trial[J]. JAMA,2014,312(14):1409-1419.
[9] JACKSON L A,CAMPBELL J D,FREY S E,et al.Effect of varying doses of a monovalent H7N9 influenza vaccine with and without AS03 and MF59 adjuvants on immune response:a randomized clinical trial[J]. JAMA,2015,314(3):237-246.
[10] WU U I,HSIEH S M,LEE W S,et al.Safety and immunogenicity of an inactivated cell culture-derived H7N9 influenza vaccine in healthy adults:a phase I/II,prospective,randomized,open-label trial[J]. Infection & Chemotherapy,2017,35(33):4099-4104.
[11] BART S A,HOHENBOKEN M,DELLA CIOPPA G,et al.A cell culture-derived MF59-adjuvanted pandemic A/H7N9 vaccine is immunogenic in adults[J]. Science Translational Medicine,2014, 6(234):234-255.
[12] MANDAN A,SEGALL N,FERGUSON M,et al.Immunogenicity and safety of an AS03-adjuvanted H7N9 pandemic influenza vaccine in a randomized trial in healthy adults[J]. Journal of Infectious Diseases,2016,214(11):1717-1727.
[13] CHADA K E,FORSHEE R,GOLDING H,et al.A systematic review and meta-analysis of cross-reactivity of antibodies induced by oil-in-water emulsion adjuvanted influenza H5N1 virus monovalent vaccines[J]. Vaccine,2017,35(24):3162-3170.
[14] 边国林,许国章,朱利利. 季节性流感疫苗接种效果观察[J].浙江预防医学,2010,22(1):12-13,19.
[15] KEITEL W A,DEKKER C L,MINK C A,et al.Safety and immunogenicity of inactivated,Vero cell culture-derived whole virus influenza A/H5N1 vaccine given alone or with aluminum hydroxide adjuvant in healthy adults[J]. Vaccine,2009,27(47):6642-6648.
[16] CHICHESTER J A,JONES R M,GREEN B J,et al.Safety and immunogenicity of a plant-produced recombinant hemagglutinin- based influenza vaccine(HAI-05)derived from A/Indonesia/05/2005(H5N1)influenza virus:a phase 1 randomized,double-blind,placebo-controlled,dose-escalation study in healthy adults[J]. Viruses,2012,4(11):3227-3244.
[17] COUCH R B,PATEL S M,WADE-BOWERS C L,et al. A randomized clinical trial of an inactivated avian influenza A(H7N7)vaccine[J] . PLoS One,2012,7(12):e49704.
[18] MADAN A,FERGUSON M,SHELDON E,et al.Immunogenicity and safety of an AS03 ajuvanted H7N1 vaccine in healthy adults:a phase I/II,observer-blind,randomized,controlled trial[J]. Vaccine,2017,35(10):1431-1439.
[19] BAI Y,SHI N,LU Q,et al.Immunological persistence of a seasonal influenza vaccine in people more 2 than 3 years old[J]. Human Vaccines & Immunother,2015,11(7):1648-1653.
[20] VESIKARI T,FORSTEN A,ARRORA A,et al.Influenza vaccination in children primed with MF59-adjuvanted or non-adjuvanted seasonal influenza vaccine[J]. Human Vaccines & Immunother,2015,11(8):2102-2112.
[21] SHNON A,KONDO M.Parents' preferences for seasonal influenza vaccine for their children in Japan[J]. Vaccine,2014,32(39):5071-5076.
[22] LI S M,LI L,AI X,et al.A randomized,controlled,blinded study of the safety,immunogenicity and batch consistency of Aleph inactivated split influenza vaccine made in China in Chinese people[J]. Human Vaccines & Immunother,2014,10(3):557-565.
[23] MANZOLI L,SALANTI G,DE VITO C,et al.Immunogenicity and adverse events of avian influenza A H5N1 vaccine in healthy adults:multiple-treatments meta-analysis[J]. The Lancet Infectious Diseases,2009,9(8):482-492.
[24] GUO Q,LIU Z,GAO J,et al.Immunogenicity and safety of pandemic influenza H5N1 vaccines in healthy adults through meta-analysis[J]. Cellular Physiology and Biochemistry,2016, 40(5):921-932. |
|
|
|
